GENETICALLY ENGINEERED HSV 1 IN MALIGNANT GLIOMA

恶性神经胶质瘤是一种几乎一致致死的中枢神经系统癌症，其在很大程度上难以用常规疗法治疗。一种有希望的新方法是在常规治疗后使用基因工程的、有条件复制的单纯疱疹病毒（HSV）来杀死剩余的肿瘤细胞。G207是一种重组HSV，缺乏在正常脑细胞中复制所必需的基因。 G207已被证明在鼠模型中有效治疗人和啮齿动物肿瘤。 在Aotus猴（Aotus nancymai）颅内接种后已确定安全性。我们假设，G207，一种基因工程HSV-1，将是安全的，并可能用于治疗恶性胶质瘤的患者有进展的疾病在MRI上的证据，尽管与传统的手术和/或活检和外部束放射治疗。 给药方式是将病毒立体定向接种到肿瘤的增强区域。

Malignant glioma is a nearly uniformly lethal cancer of the central nervous system that is largely refractory to conventional modalities of therapy. One promising new approach is the use of a genetically engineered, conditionally replicating herpes simplex virus (HSV) following conventional therapy to kill remaining tumor cells. G207 is a recombinant HSV lacking genes essential for replication in normal brain cells. G207 has been shown to be efficacious in the treatment of both human and rodent tumors in murine models. Safety has been established following intracranial inoculation in the Aotus monkey (Aotus nancymai). We hypothesize that G207, a genetically-engineered HSV-1, will be safe and potentially useful for the treatment of patients with malignant gliomas who have evidence of progressive disease on MRI despite treatment with conventional surgery and/or biopsy and external beam radiation. The mode of administration will be stereotactic inoculation of virus into an enhancing region of the tumor.